TARGIT - A

New insights from the TARGIT A trial 2021

Dr. Jayant Vaidya

Review of 'scientific validation' of the TARGIT-A long-term outcomes

Dr. Valery Uhl

Review of 'treatment efficiency' of the TARGIT - A long-term outcomes

Dr. William Small

New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer

The long-term results of the TARGIT-A randomised trial confirmed that TARGIT-IORT is as effective and safer than whole breast radiotherapy.

Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) to improve breast cancer treatment – better for patients, better for health care systems

Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer:5-year results for local control and overall survival from the TARGIT-A randomised trial

Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer

Effect of Delayed Targeted Intraoperative Radiotherapy vs. Whole-Breast Radiotherapy on Local Recurrence and Survival